Featured Research

from universities, journals, and other organizations

Halting Histamine Action Means Hallelujah For Hay Fever Sufferers

Date:
May 7, 2006
Source:
Journal of Clinical Investigation
Summary:
Histamine release during asthma and hay fever causes itching and wheezing. Northwestern University researchers examined a mouse model of asthma and found that mice lacking the histamine 1 receptor (H1R) could still mount a Th2 immune response to allergic antigens, but did not develop airway inflammation. Without histamine binding to H1R, T cells were not recruited to the site of allergen exposure -- the lung. Blocking H1R with currently available drugs might have benefit for patients.

In allergic diseases such as asthma, hay fever, and rhinitis an allergen stimulates the release of antibodies that attach themselves to mast cells causing these cells to release histamine, which can cause symptoms like itching of the nose, skin and eyes, sneezing, and wheezing.

The characteristic "Th2 immune response" observed in allergy sufferers is an acquired immune response whose most prominent feature is high antibody production relative to the amount of cytotoxic T cells. Classical antihistamine drugs bind to but do not activate the histamine 1 receptor (H1R), subsequently blocking the allergic response.

Interestingly, a recent study in Nature reported that mice deficient in H1Rs were still able to mount a Th2 immune response. In an effort to clarify this discrepancy, Paul Bryce and colleagues from Northwestern University, Chicago, examined H1R-/- mice with asthma and in their study appearing online on May 4 in advance of print publication in the June issue of the Journal of Clinical Investigation, these authors report a previously unknown role for H1R in the development of inflammatory airway responses.

They found that these mice do indeed possess a dominant Th2 immune response to allergic antigens, yet they do not develop airway inflammation. Bryce et al. show that this is because the T cells in these mice are not able to travel to the site of allergen exposure -- the lung. Histamine was found to act as an attractant for T cells and with no H1Rs present for histamine to bind to, the T cells were not recruited to the lung or able to cause the characteristic inflammatory allergic response in these mice.

This advancement of our understanding of the roles of histamine in allergic disease indicates that blocking H1R with currently available drugs might have potential benefit for patients.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Halting Histamine Action Means Hallelujah For Hay Fever Sufferers." ScienceDaily. ScienceDaily, 7 May 2006. <www.sciencedaily.com/releases/2006/05/060507212741.htm>.
Journal of Clinical Investigation. (2006, May 7). Halting Histamine Action Means Hallelujah For Hay Fever Sufferers. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/05/060507212741.htm
Journal of Clinical Investigation. "Halting Histamine Action Means Hallelujah For Hay Fever Sufferers." ScienceDaily. www.sciencedaily.com/releases/2006/05/060507212741.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins